Net Worth Advisory Group Acquires New Holdings in Natera, Inc. (NASDAQ:NTRA)

Net Worth Advisory Group acquired a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,570 shares of the medical research company's stock, valued at approximately $505,000.

Other institutional investors also recently bought and sold shares of the company. Principal Securities Inc. boosted its holdings in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC boosted its stake in shares of Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock valued at $574,000 after acquiring an additional 61 shares during the last quarter. Fulton Bank N.A. boosted its stake in Natera by 2.0% in the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after buying an additional 71 shares during the last quarter. Colonial Trust Co SC lifted its stake in shares of Natera by 7.8% in the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock valued at $210,000 after purchasing an additional 96 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC raised its holdings in shares of Natera by 3.6% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 2,812 shares of the medical research company's stock valued at $445,000 after buying an additional 98 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Gail Boxer Marcus sold 4,000 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $164.44, for a total value of $657,760.00. Following the transaction, the director now directly owns 5,704 shares in the company, valued at approximately $937,965.76. This represents a 41.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 2,562 shares of Natera stock in a transaction on Monday, March 31st. The shares were sold at an average price of $138.41, for a total transaction of $354,606.42. Following the completion of the sale, the chief financial officer now owns 75,557 shares in the company, valued at approximately $10,457,844.37. This trade represents a 3.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 68,275 shares of company stock worth $10,142,783 in the last ninety days. Company insiders own 7.60% of the company's stock.

Natera Trading Up 0.6%

NTRA stock traded up $0.99 during midday trading on Friday, reaching $165.34. 729,330 shares of the company's stock traded hands, compared to its average volume of 1,410,918. The business has a 50-day moving average price of $154.56 and a two-hundred day moving average price of $158.46. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company has a market capitalization of $22.58 billion, a P/E ratio of -93.94 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business's quarterly revenue was up 36.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.56) earnings per share. Equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

NTRA has been the subject of a number of analyst reports. Robert W. Baird boosted their price target on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Royal Bank of Canada started coverage on Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price for the company. Piper Sandler increased their target price on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Canaccord Genuity Group reissued a "buy" rating and issued a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Finally, BTIG Research reiterated a "buy" rating on shares of Natera in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $184.63.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.